secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001493152-25-009775
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma appoints Keith Murphy and Edward Neugeboren to board; two directors resign
--------------------------------------------------------------------------------

- Natasha Giordano and Matthew Wikler resigned from the Board effective Feb 11, 2025, not due to any disagreement.
- Keith Murphy (Organovo Executive Chairman) appointed director, Chair of Governance Committee, Compensation Committee member.
- Edward Neugeboren (Cronus Pharma Chief Strategy Officer) appointed director, Chair of Compensation, Audit Committee member.
- Neugeboren qualifies as audit committee financial expert; both are independent under NYSE and SEC rules.
- New directors bring significant healthcare, biotech, and capital markets experience; effective March 11, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225009775/0001493152-25-009775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315225009775/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer